Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO3WEG)

Drug Name
RU-56187 Drug Info
Synonyms
RU-56187; 143782-25-6; CHEMBL1099140; 4-(3,4,4-Trimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-2-(trifluoromethyl)benzonitrile; Benzonitrile,2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-; RU 56187; ACMC-20n377; AC1L318J; SCHEMBL1435262; CTK4C3806; DTXSID90162545; BDBM50317664; 2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)benzonitrile; 2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile; Benzonitrile, 2-(trifluoromethyl)-4-(3,4,4-trimet
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
132581
CAS Number
CAS 143782-25-6
TTD Drug ID
DMO3WEG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Androgen receptor messenger RNA (AR mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dihydrotestosterone DM3S8XC Prostate hyperplasia GA90 Phase 4 [2]
BAY 86-5044 DMRZLU4 Breast cancer 2C60-2C65 Phase 2 [3]
TRC-253 DMXI8CD Prostate cancer 2C82.0 Phase 1/2 [4]
IONIS-AR-2.5Rx DMF2DMS Prostate cancer 2C82.0 Phase 1/2 [5]
ISIS-AR DM8P3N5 Prostate cancer 2C82.0 Phase 1 [6]
EZN-4176 DMNPS59 Prostate cancer 2C82.0 Phase 1 [7]
EUGENOL DM7US1H Discovery agent N.A. Patented [8]
RU-58841 DMMEAZ2 Acne vulgaris ED80 Discontinued in Phase 1 [9]
flavone DMEQH6J Discovery agent N.A. Investigative [10]
APIGENIN DMI3491 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Androgen receptor messenger RNA (AR mRNA) TTKPW01 ANDR_HUMAN Inhibitor [1]

References

1 Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists. Bioorg Med Chem. 2010 May 1;18(9):3159-68.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
3 Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. Expert Opin Pharmacother. 2019 Feb;20(2):163-172.
6 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
7 2011 Pipeline of Santaris Pharma.
8 Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2111-4.
9 Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
10 Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.